Tchem MMP2 72 kDa type IV collagenase

Protein Summary

Description

Ubiquitinous metalloproteinase that is involved in diverse functions such as remodeling of the vasculature, angiogenesis, tissue repair, tumor invasion, inflammation, and atherosclerotic plaque rupture. As well as degrading extracellular matrix proteins, can also act on several nonmatrix proteins such as big endothelial 1 and beta-type CGRP promoting vasoconstriction. Also cleaves KISS at a Gly-|-Leu bond. Appears to have a role in myocardial cell death pathways. Contributes to myocardial oxidative stress by regulating the activity of GSK3beta. Cleaves GSK3beta in vitro. Involved in the formation of the fibrovascular tissues in association with MMP14. PEX, the C-terminal non-catalytic fragment of MMP2, posseses anti-angiogenic and anti-tumor properties and inhibits cell migration and cell adhesion to FGF2 and vitronectin. Ligand for integrinv/beta3 on the surface of blood vessels. Isoform 2: Mediates the proteolysis of CHUK/IKKA and initiates a primary innate immune response by inducing mitochondrial-nuclear stress signaling with activation of the pro-inflammatory NF-kappaB, NFAT and IRF transcriptional pathways. This gene is a member of the matrix metalloproteinase (MMP) gene family, that are zinc-dependent enzymes capable of cleaving components of the extracellular matrix and molecules involved in signal transduction. The protein encoded by this gene is a gelatinase A, type IV collagenase, that contains three fibronectin type II repeats in its catalytic site that allow binding of denatured type IV and V collagen and elastin. Unlike most MMP family members, activation of this protein can occur on the cell membrane. This enzyme can be activated extracellularly by proteases, or, intracellulary by its S-glutathiolation with no requirement for proteolytical removal of the pro-domain. This protein is thought to be involved in multiple pathways including roles in the nervous system, endometrial menstrual breakdown, regulation of vascularization, and metastasis. Mutations in this gene have been associated with Winchester syndrome and Nodulosis-Arthropathy-Osteolysis (NAO) syndrome. Alternative splicing results in multiple transcript variants encoding different isoforms. [provided by RefSeq, Oct 2014]

Uniprot Accession IDs

• P08253
• B2R6U1
• B4DWH3
• E9PE45
• Q9UCJ8

Gene Name

• MMP2

Ensembl ID

• ENST00000219070
• ENSP00000219070
• ENSG00000087245
• ENST00000437642
• ENSP00000394237
• ENST00000543485
• ENSP00000444143
• ENST00000570308
• ENSP00000461421

Symbol

• CLG4A
• CLG4
• MONA
• CLG4A
• MMP-2
• TBE-1
• MMP-II

Knowledge Table

Most Knowledge About	Knowledge Value (0 to 1 scale)
chemical	1
protein domain	1
kinase perturbation	0.91
PubMedID	0.81
disease	0.74

Protein Classes

PANTHER Classes

Protein / ... / Metalloprotease / 72 Kda Type Iv Collagenase

DTO Classes

Protein / Enzyme / Protease / Metalloprotease / 72 Kda Type Iv Collagenase

IDG Development Level Summary

Tdark

These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:

Pubmed score: 8231.48   (req: < 5)

Gene RIFs: 1778   (req: <= 3)

Antibodies: 1510   (req: <= 50)

Tbio

These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:

Pubmed score: 8231.48   (req: >= 5)

Gene RIFs: 1778   (req: > 3)

Antibodies: 1510   (req: > 50)

- OR - satisfy the following criterion:

Gene Ontology Terms: 20

Tchem

Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions

Active Ligands: 2393

Tclin

Target has at least one approved drug - AND - satisfies the preceding conditions

Active Drug: 0